|
gptkbp:instanceOf
|
gptkb:drug
gastroprokinetic agent
|
|
gptkbp:approvedBy
|
1988
|
|
gptkbp:ATCCode
|
A03FA02
|
|
gptkbp:blackBoxWarning
|
yes
|
|
gptkbp:brand
|
Propulsid
|
|
gptkbp:CASNumber
|
81098-60-4
|
|
gptkbp:chemicalClass
|
benzamide derivative
|
|
gptkbp:contraindication
|
patients taking CYP3A4 inhibitors
patients with prolonged QT interval
|
|
gptkbp:discoveredBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:eliminationHalfLife
|
10 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C23H29ClFN3O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cisapride
|
|
gptkbp:KEGGID
|
D00216
|
|
gptkbp:legalStatus
|
withdrawn in many countries
restricted use in some countries
|
|
gptkbp:mechanismOfAction
|
5-HT4 receptor agonist
increases acetylcholine release
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
465.95 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
2667
2769
CHEMBL1327
DB00604
|
|
gptkbp:riskFactor
|
electrolyte imbalance
pre-existing heart disease
concurrent use with CYP3A4 inhibitors
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
gptkb:torsades_de_pointes
nausea
diarrhea
abdominal pain
constipation
headache
QT prolongation
|
|
gptkbp:synonym
|
Propulsid
cisapride monohydrate
|
|
gptkbp:UNII
|
3M8L1G6G0W
|
|
gptkbp:usedFor
|
gptkb:gastroesophageal_reflux_disease
gastroparesis
|
|
gptkbp:withdrawn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:United_States
|
|
gptkbp:bfsParent
|
gptkb:Erythromycin
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|